Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Truist Securities Reiterates Buy on Carlsmed, Raises Price Target to $20

Author: Benzinga Newsdesk | November 07, 2025 10:49am

Truist Securities analyst Richard Newitter reiterates Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.

Posted In: CARL